Sepsis Diagnostics Market Report 2026

Sepsis Diagnostics Market Overview

• Sepsis Diagnostics market size has reached to $1.07 billion in 2025 • Expected to grow to $1.57 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rising Hospital-Acquired Infections Fueling The Growth Of The Market Due To Increasing Antibiotic Resistance And Complications • Market Trend: Innovative Diagnostic Solutions Enhancing Patient Safety And Optimizing Sepsis Testing Accuracy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sepsis Diagnostics Market?

Sepsis diagnostics refers to a range of advanced technologies and tests designed to quickly detect the presence of sepsis, a critical condition that can lead to organ failure and death if left untreated. These technologies enable healthcare providers to assess the severity of the condition and make timely, informed decisions to initiate appropriate treatment and improve patient survival rates. The main products in sepsis diagnostics include instruments, blood culture media, assay kits and reagents, and software. Instruments are medical devices used to rapidly analyze blood samples and detect pathogens, enabling early and accurate identification of sepsis for timely treatment. Sepsis diagnostics utilize various technologies such as microbiology, molecular diagnostics, immunoassays, flow cytometry, and other technologies to detect different types of pathogens, including bacterial sepsis, fungal sepsis, viral sepsis, and other pathogens. The diagnostic methods include automated diagnostics and conventional diagnostics. These methods are used by various end-users, such as hospitals and clinics, pathology and reference laboratories, and research institutes.

What Is The Sepsis Diagnostics Market Growth Forecast?

The sepsis diagnostics market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to AI-enabled diagnostic platforms, expansion of biomarker-based testing, tele-diagnostic integration, novel sepsis detection assays, growth of point-of-care diagnostics. Major trends in the forecast period include point-of-care diagnostic devices, biomarker-based tests, rapid blood culture kits, AI-assisted diagnostic platforms, integration with hospital IT systems.

Global Sepsis Diagnostics Market Segmentation

1) By Product: Instruments, Blood Culture Media, Assay Kits And Reagents, Software 2) By Technology: Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Other Technologies 3) By Pathogen: Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, Other Pathogens 4) By Method: Automated Diagnostics, Conventional Diagnostics 5) By End-Users: Hospitals And Clinics, Pathology And Reference Laboratories, Research Institutes Subsegments: 1) By Instruments: Automated Analyzers, Point-Of-Care (PoC) Testing Devices, Microfluidic-Based Devices, Polymerase Chain Reaction (PCR) Instruments, Flow Cytometers 2) By Blood Culture Media: Aerobic Blood Culture Media, Anaerobic Blood Culture Media, Mycobacteria Blood Culture Media, Pediatric Blood Culture Media, Fungal Blood Culture Media 3) By Assay Kits And Reagents: Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Polymerase Chain Reaction (PCR) Assay Kits, Immunoassay Reagents, Molecular Diagnostic Reagents, Biosensor-Based Assay Kits 4) By Software: Data Management Software, Laboratory Information Systems (LIS), Artificial Intelligence (AI)-Based Diagnostic Tools, Predictive Analytics Software, Cloud-Based Diagnostic Platforms

What Is The Driver Of The Sepsis Diagnostics Market?

The rising incidence of hospital-acquired infections is expected to propel the growth of the sepsis diagnostics market going forward. Hospital-acquired infections (HAIs) are infections that develop during or after a patient’s stay in a healthcare facility, typically 48 hours or more after admission, and were not present at the time of admission. The rising incidence of hospital-acquired infections is due to an increase in antibiotic resistance. Overuse and misuse of antibiotics in healthcare settings led to the development of resistant bacteria, making infections harder to treat. Sepsis diagnostics helps detect hospital-acquired infections early by identifying pathogens and biomarkers, enabling timely treatment and reducing complications. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022–23, HACs were observed in 2% of public hospital admissions and 0.8% of private hospital admissions, with healthcare-associated infections being the most frequent complication. Therefore, the rising incidence of hospital-acquired infections drives growth in the sepsis diagnostics industry.

Key Players In The Global Sepsis Diagnostics Market

Major companies operating in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMérieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., EKF Diagnostics Holdings plc, Boditech Med Inc., Alifax S.r.l., Abionic SA

Global Sepsis Diagnostics Market Trends and Insights

Major companies operating in the sepsis diagnostics market are focusing on developing innovative solutions, such as culture-free diagnostic solutions, to enable rapid and accurate detection of sepsis without relying on traditional blood cultures. A culture-free diagnostic solution is a method of detecting pathogens or infections without the need for traditional microbial culture techniques. These solutions rely on advanced technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays to rapidly identify pathogens directly from patient samples such as blood, saliva, or tissue. For instance, in April 2024, Deepull Diagnostics S.L., a Spain-based manufacturing company, launched the UllCORE diagnostic system for early sepsis detection. The UllCORE system is a benchtop, culture-free multiplex PCR platform developed by Deepull for rapid pathogen identification in sepsis and other acute infections. It extracts microbial DNA from 8 mL of whole blood and provides 50 reportable results within one hour. The system detects 95% of sepsis-causing pathogens, including bacteria, fungi, and antibiotic resistance genes. Designed to improve early diagnosis and reduce antibiotic misuse, UllCORE supports hospitals combating antimicrobial resistance.

What Are Latest Mergers And Acquisitions In The Sepsis Diagnostics Market?

In October 2024, Trinity Biotech plc, an Ireland-based medical laboratory company, acquired a 12.5% stake in Novus Diagnostics Ltd for $2.5 million. With this acquisition, Trinity Biotech aims to accelerate the development and commercialization of Novus Diagnostics’ rapid point-of-care diagnostic solutions, particularly its 15-minute bloodstream infection test, to improve sepsis diagnosis and patient outcomes. Novus Diagnostics Ltd. is an Ireland-based medical technology company developing rapid point-of-care diagnostic solutions for bloodstream infections, including sepsis.

Regional Outlook

North America was the largest region in the sepsis diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sepsis Diagnostics Market?

The sepsis diagnostics market consists of revenues earned by entities by providing services such as clinical consultation, rapid diagnostic testing solutions, point-of-care diagnostic solutions, biomarker testing, and molecular diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis diagnostics market also includes sales of sepsis diagnostic test kits, automated blood culture systems, molecular diagnostic equipment, sepsis biomarker assay kits, and rapid diagnostic devices for infection detection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sepsis Diagnostics Market Report 2026?

The sepsis diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.